Evgen Pharma PLC Paper on SFX-01 in ER positive breast cancer
08 Junho 2020 - 3:00AM
RNS Non-Regulatory
TIDMEVG
Evgen Pharma PLC
08 June 2020
Evgen Pharma plc
("Evgen" or the "Company")
Paper published on SFX-01 in ER positive breast cancer
Evgen Pharma plc (AIM: EVG), a clinical stage drug development
company focused on the treatment of cancer and neurological
conditions, announces the publication of a scientific paper
entitled " Targeting STAT3 signaling using stabilised sulforaphane
(SFX-01) inhibits endocrine resistant stem-like cells in
ER-positive breast cancer". SFX-01 is the Company's synthetic
formulation of stabilised sulforaphane (SFN).
The paper, in the prestigious journal Oncogene, is co-authored
by Bruno Simoes, Research Fellow at the Division of Molecular &
Clinical Cancer Sciences, The University of Manchester and Sacha
Howell, Honorary Consultant in Medical Oncology at the Christie
Hospital. The paper describes a body of work carried out in a
collaboration between Evgen and the University of Manchester, over
a number of years, on the potential use SFX-01 to combat endocrine
resistance in ER-positive breast cancer.
The paper reports that SFX--01, used in combination with
endocrine therapies, prevents breast cancer stem-like cell (CSC)
enrichment in patient samples and patient-derived xenograft
tumours. Thus SFX-01 reduces the formation of stem-like cells
(thought to be the clones that survive once tumours are treated
with therapies such as endocrine therapies, and which cause
metastases). SFX-01 also blocks STAT-3, itself implicated in
resistance to endocrine therapies. SFX-01 therefore has the
potential to overcome such resistance and improve clinical
outcomes.
The paper can be viewed at: https://rdcu.be/b4uXz and on the
Evgen website.
Barry Clare, Executive Chairman of Evgen, commented:
"This paper clearly elucidates the potential of SFX-01 in the
treatment of ER+ metastatic breast cancer and its potential as a
STAT3 inhibitor. We look forward to building on this work, and on
the data from our successful phase II trial in metastatic breast
cancer, in the next trial."
Enquiries:
Evgen Pharma plc www.evgen.com via Walbrook
Barry Clare, Chairman
Richard Moulson, CFO
finnCap www.finncap.com +44 (0)20 7220 0500
Geoff Nash / Teddy Whiley (Corporate
Finance)
Alice Lane (ECM)
Walbrook PR +44 (0)20 7933 87870 or evgen@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7876
Paul McManus / Anna Dunphy 741 001
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company
developing sulforaphane based medicines for the treatment of
multiple diseases . The Company's core technology is Sulforadex
(R), a method for synthesising and stabilising the naturally
occurring compound sulforaphane and novel proprietary analogues
based on sulforaphane. The lead product, SFX-01, is a patented
composition of synthetic sulforaphane and alpha-cyclodextrin.
Clinical data from the Company's open-label Phase II STEM trial
has shown that SFX-01 can halt the growth of progressing tumours in
patients with oestrogen-positive (ER+) metastatic breast cancer,
and in some cases significantly shrink the tumour, whilst causing
very few side effects.
The Company has its headquarters at The Colony, Wilmslow,
Cheshire, and its registered office is at the Liverpool Science
Park, Liverpool. It joined the AIM market of the London Stock
Exchange in October 2015 and trades under the ticker symbol
EVG.
For further information, please visit: www.evgen.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAFRMPTMTTMBLM
(END) Dow Jones Newswires
June 08, 2020 02:00 ET (06:00 GMT)
Evgen Pharma (LSE:EVG)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Evgen Pharma (LSE:EVG)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
